Pleasanton, United States
Taimei Technology is a digital innovator in the R&D and Life Science Industries, with a mission to accelerate the accessibility of innovative drugs. Founded in 2013, the company has developed TrialOS, an industry-leading, integrated digital platform dedicated to clinical research. This platform offers in-depth insights into drug R&D, pharmacovigilance, marketing and sales, and market access.
Operating from the United States, Taimei Technology's unified digital platform integrates advanced AI, big data, cloud computing, and mobile technologies to provide innovative solutions to industry stakeholders across the entire product life cycle. The company is spearheading the construction of the infrastructure for the future of the life science industry, with the objective of accelerating product launches, improving quality, enhancing drug safety, improving drug accessibility, and reducing the medical burden on patients and providers.
The company's most recent milestone was a CNY1.20B Venture Round investment at 28 September 2020, which was backed by a notable group of investors including Future Ventures, ZSVC, Cowin Venture, Matrix Partners China, FanZhuo Capital, Tencent, YF Capital, Ivy Capital, Softbank China & India Holdings, and GL Ventures LLC. This substantial investment reflects confidence in Taimei Technology's vision and potential to drive significant impact in the life science industry.
-logo.jpg "Drug Safety Navigator (DSN)"){kind=logo}
